Kanna

Most of the commercial and scientific attention on Sceletium tortuosum has historically centred on mesembrine, the alkaloid most associated with the plant's mood-elevating reputation. Research from Pérez-Ranea, de Ceglia, Fuentes-Ríos and colleagues has now turned to a less-studied corner of the plant's chemistry, isolating minor mesembrine-type alkaloids and identifying a new compound, normesembrenone, with anxiolytic-like activity in laboratory testing. The significance here sits less in any single finding and more in what it suggests about kanna's chemical complexity. A plant marketed for decades on the strength of one well-known compound is turning out to contain a wider family of related alkaloids, each with potentially distinct effects worth investigating on their own terms rather than treating as minor variants of mesembrine. Separately, a 2026 study published in Phytomedicine Plus by de Jong, van Niekerk and van der Kooy raises a quality-control concern directly relevant to anyone using kanna products for wellness purposes. The researchers found meaningful variation in mesembrine-alkaloid content between non-standardised kanna products and Zembrin, a patented, standardised commercial extract, with differences even detected across batches with different expiry dates. This matters practically. Two products both labelled as kanna extract may deliver substantially different alkaloid doses depending on whether they come from a standardised or non-standardised source. This information is provided for educational purposes and does not constitute medical advice. Anyone considering kanna for anxiety, mood, or any other health concern should consult a qualified healthcare professional before use.

Patent activity is often one of the clearer signals of where serious commercial research investment is heading, well before products reach a shelf. US patent US12059404B2, filed in connection with Sensorium Therapeutics and the University of Stellenbosch, covers mesembrenol and mesembranol specifically, two alkaloids present in Sceletium tortuosum that have historically sat in mesembrine's shadow despite belonging to the same chemical family. The patent's own framing describes Zembrin, the established standardised Sceletium extract, as having low reported side effects, and positions this newer composition work as building on that safety profile while targeting different components of the plant's alkaloid mix. University involvement, in this case Stellenbosch, alongside a dedicated therapeutics company suggests a deliberate, longer-term research programme rather than an isolated filing. This pairs directly with the standardisation research described in Phytomedicine Plus, which found real variation in mesembrine-alkaloid content across non-standardised kanna products. Read together, these two developments point toward an industry actively working to move kanna from a loosely defined herbal product category into a more precisely characterised, patent-protected botanical ingredient space, the kind of shift that typically precedes a wider set of pharmaceutical-adjacent product launches.

Sceletium tortuosum holds a distinction few South African plants share: it is one of the oldest mesembs known to the Western world, first encountered by European colonisers at the Cape in the seventeenth century and cultivated in England since 1732, according to SANBI's own botanical record. Carl von Linnaeus formally described and named the species in 1753, more than a century after it was already known to European settlers. What SANBI's record states plainly, and what deserves equal weight to those European dates, is that it was the Khoisan people of South Africa, using the plant in folk medicine long before any of this documentation began, who introduced kanna's mood-elevating properties to the Western world in the first place. The knowledge did not originate with colonisation. It was carried into colonial awareness by people who already held it. This history matters directly to how kanna is understood today. The plant's current commercialisation as an anti-anxiety and mood-support product draws on chemistry the Khoisan had already identified and applied through direct, generational engagement with the plant, centuries before mesembrine was isolated in any laboratory.

Herbalgram's herb profile, published in March 2026, describes Sceletium tortuosum as one of the most commercially promising native plants of South Africa, and confirms that commercial cultivation sites have now been established for the species. This is a meaningful practical development rather than an aspirational industry statement, since it directly addresses the conservation pressure on wild kanna populations that SANBI's own record explicitly flags as tremendous. Establishing viable commercial cultivation for a plant with kanna's specific agronomic requirements, a narrow autumn-to-spring planting window and a strict no-irrigation summer rest period, is not a trivial undertaking. Getting cultivation right at commercial scale typically requires years of trial plots before yields and alkaloid consistency are reliable enough to support a genuine supply chain. The practical test for this development will be whether cultivated kanna can match wild-harvested material closely enough in alkaloid content to satisfy both the standardisation concerns raised in recent Zembrin research and the broader commercial market's quality expectations, rather than simply existing as a parallel, lower-quality supply stream running alongside continued wild harvest.

Market research from Market Intelo, published in June 2026, values the global kanna Sceletium supplements market at 0.3 billion US dollars in 2025, with projected growth to 0.6 billion US dollars by 2034, an annual growth rate of 7.8 percent over that period. This sits within a considerably larger adaptogens market, which Fortune Business Insights values at a projected 22.46 billion US dollars by 2034, and which Future Market Insights separately places at 8.96 billion US dollars in 2025, growing toward 9.26 billion in 2026 alone. The specific figures across these three reports differ, which is typical of market sizing research generally, where methodology and category definitions vary between firms. What is consistent across all three is a clear growth trajectory for both kanna specifically and adaptogens broadly, at a rate meaningfully outpacing general consumer goods categories. For South African producers and commercial partners, kanna's position within this growth is worth noting carefully rather than assuming automatically favourable. A smaller, specific category growing inside a much larger adaptogens boom can benefit from rising general consumer interest in the space, but it also faces competition from better-funded, more heavily marketed adaptogen ingredients originating elsewhere, meaning market share within the category is not guaranteed simply by overall sector growth. This is market observation, not investment advice, and any commercial decision should be made with independent financial guidance.

Patent US12059404B2, associated with Sensorium Therapeutics and the University of Stellenbosch, covers compositions involving mesembrenol and mesembranol, two Sceletium tortuosum alkaloids. This sits alongside the existing patented status of Zembrin, the standardised extract that has anchored most of kanna's commercial and clinical development to date. For a plant with deep roots in Khoisan traditional knowledge, patent activity of this kind raises a question worth naming plainly rather than avoiding. Intellectual property protection over specific extraction methods or alkaloid compositions is a different legal category from ownership of the plant or the traditional knowledge that first identified its properties, and South African bioprospecting law under the Biodiversity Act generally requires benefit-sharing arrangements with knowledge-holding communities before commercial access proceeds. Whether this specific patent, or the broader body of kanna-related patent activity, includes such arrangements with Khoisan communities is not something confirmed in the patent record itself, and is worth flagging as an open question rather than assuming either a positive or negative answer. The existence of continued, active patent filing around kanna's individual alkaloids, well beyond mesembrine alone, signals an industry treating the plant's chemistry as a genuinely deep and still only partially mapped resource.